scholarly journals Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study

2014 ◽  
Vol 69 (9) ◽  
pp. 2556-2562 ◽  
Author(s):  
Csaba Fehér ◽  
Montserrat Rovira ◽  
Alex Soriano ◽  
Jordi Esteve ◽  
José Antonio Martínez ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Clinical Outcome ◽  
Observational Study ◽  
Retrospective Observational Study ◽  
Extended Infusion

Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study

2015 ◽  
Vol 14 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Johann Willeit ◽  
Theresa Geley ◽  
Johannes Schöch ◽  
Heinrich Rinner ◽  
Andreas Tür ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Observational Study ◽  
Retrospective Observational Study

scholarly journals Presenting characteristics and clinical outcome of patients with COVID-19 in South Korea: A nationwide retrospective observational study

2020 ◽  
Vol 5 ◽  
pp. 100061
Author(s):  
Hyun-Young Park ◽  
Jung Hyun Lee ◽  
Nam-Kyoo Lim ◽  
Do Sang Lim ◽  
Sung Ok Hong ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Observational Study ◽  
South Korea ◽  
Retrospective Observational Study

Hemmkörperentwicklung bei Hämophilie-Patienten nach Präparate wechsel

2012 ◽  
Vol 32 (S 01) ◽  
pp. S39-S42 ◽  
Author(s):  
S. Kocher ◽  
G. Asmelash ◽  
V. Makki ◽  
S. Müller ◽  
S. Krekeler ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Observational Study ◽  
Retrospective Observational Study ◽  
Frequent Change ◽  
Patient Age ◽  
Treatment Regimens ◽  
Patient Âgé ◽  
The Relationship ◽  
Observation Period

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.

Sign in / Sign up

Export Citation Format

Share Document